Erytech is a biopharmaceutical company that was founded in Lyon, France in 2004. They specialize in the development of innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. With a focus on patients with high unmet medical needs, Erytech leverages two proprietary platforms: ERYCAPS and ERYCEV.

ERYCAPS utilizes a novel technology to encapsulate drug substances inside red blood cells, while ERYCEV explores the potential of drug-loaded extracellular vesicles derived from red blood cells. Listed on the Nasdaq Global Select Market in the United States and on the Euronext regulated market in Paris, Erytech is committed to delivering effective treatments to patients. They are part of various indexes, including CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150, and Next Biotech.

Erytech is dedicated to advancing healthcare through their innovative therapies and is poised to make a significant impact in the field of biopharmaceuticals